Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen s Investigation Into Revenue Issues Holds Up Q3 Financials

NEW YORK, Nov. 7 (GenomeWeb News) - Ciphergen said today that its audit committee is investigating the recognition of around $500,000 in sales recorded in the second quarter.


As a result, the company, which has enlisted the help of undisclosed "external accounting advisors," said it is delaying the release of its third-quarter financial results.


Last Wednesday, a notice on Ciphergen's web site said the company planned to issue its third-quarter earnings the following day. However, that notice had been removed when a GenomeWeb News reporter revisited the site on Thursday. A Ciphergen spokeswoman said last week the notice had been posted on the web site in error.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.